. 2020 Apr 15;8(6):539–541. doi: 10.1016/S2213-2600(20)30172-7

Table.

Clinical studies of hydroxychloroquine in patients with COVID-19

	Study type (number of patients)	Treatment	Duration	Control group (number of patients)	Primary outcome	Clinical outcomes	ICU patients (n/N)	Adverse events (n/N)	Mortality (n/N)
Gautret et al⁸	Prospective open-label, non-randomised trial (n=42)	Hydroxychloroquine (200 mg every 8 h) alone (n=14) or with azithromycin (500 mg on day 1, 250 mg on days 2–5; n=6)	10 days	Yes (n=16)	Viral load (nasopharyngeal swab): presence or absence of SARS-CoV-2 at day 6	NR	0/36	NR	0/36
Gautret et al⁹	Prospective observational study (n=80)	Hydroxychloroquine (200 mg every 8 h) and azithromycin (500 mg on day 1, 250 mg on days 2–5)	10 days	No	Disease progression: need for oxygen or ICU admission	Viral load, hospital length of stay	3/80	7/80	1/80
Chen et al¹²	RCT (n=30)	Hydroxychloroquine (200 mg every 12 h)	7 days	Yes (n=15)	Viral load (nasopharyngeal swab): presence of SARS-CoV-2 at day 7	NR	0/30	4/15	0/30
Chen et al¹³	RCT (n=62)	Hydroxychloroquine (200 mg every 12 h)	5 days	Yes (n=31)	Time to clinical recovery	Pulmonary recovery, adverse events	0/62	2/31	0/62
Molina et al¹⁴	Prospective observational study (n=11)	Hydroxychloroquine (200 mg every 8 h) and azithromycin (500 mg on day 1, 250 mg on days 2–5)	10 days	No	Viral load (nasopharyngeal swab): presence of SARS-CoV-2 on days 5–6	NR	2/11	1/11	1/11

COVID-19=coronavirus disease 2019. ICU=intensive care unit. NR=not reported. RCT=randomised controlled trial. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.